170 related articles for article (PubMed ID: 37897136)
1. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
Shalabi H; Harrison C; Yates B; Calvo KR; Lee DW; Shah NN
Pediatr Blood Cancer; 2024 Jan; 71(1):e30741. PubMed ID: 37897136
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome.
Asawa P; Vusqa U; Khan C; Samhouri Y; Fazal S
Anticancer Res; 2022 Aug; 42(8):3853-3856. PubMed ID: 35896259
[TBL] [Abstract][Full Text] [Related]
3. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
4. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
5. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
7. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
Tan AP
Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
[TBL] [Abstract][Full Text] [Related]
9. Severe persistent neurotoxicity associated with CAR T therapy in children.
Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
[TBL] [Abstract][Full Text] [Related]
10. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
Catalá E; Iacoboni G; Vidal-Jordana Á; Oristrell G; Carpio C; Vilaseca A; Cabirta A; Bosch F; Tintoré M; Barba P
Hematol Oncol; 2022 Aug; 40(3):482-487. PubMed ID: 35139240
[TBL] [Abstract][Full Text] [Related]
12. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
Hashmi H; McGann M; Greenwell BI
J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
[TBL] [Abstract][Full Text] [Related]
13. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
14. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
[TBL] [Abstract][Full Text] [Related]
15. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.
Sheth VS; Gauthier J
Bone Marrow Transplant; 2021 Mar; 56(3):552-566. PubMed ID: 33230186
[TBL] [Abstract][Full Text] [Related]
16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
17. Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
Katsin M; Shman T; Migas A; Lutskovich D; Serada Y; Khalankova Y; Kostina Y; Dubovik S
Front Immunol; 2024; 15():1380451. PubMed ID: 38765003
[TBL] [Abstract][Full Text] [Related]
18. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
19. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
20. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]